Update on treatment guidelines for acute bacterial sinusitis.

Area of Science:

• Infectious Diseases
• Pharmacology
• Public Health

Background:

• Acute bacterial sinusitis (ABS) frequently follows viral infections, causing significant patient morbidity and economic burden.
• Current management strategies for ABS aim to optimize clinical outcomes and minimize antimicrobial resistance.
• National health authorities provide guidelines for the rational selection of antibacterial therapy.

Purpose of the Study:

• To provide an overview of current guidelines for managing acute bacterial sinusitis.
• To highlight clinical significance of variations in treatment recommendations.
• To discuss emerging treatment options, including the ketolide telithromycin.

Main Methods:

• Review of current national health authority guidelines for ABS management.
• Analysis of treatment recommendations and variations therein.
• Inclusion of information on new therapeutic options.

Main Results:

• Guidelines aim for rational antibacterial selection to improve outcomes and combat resistance.
• Variations in treatment recommendations exist across different national guidelines.
• Telithromycin, a ketolide, has been added to several national treatment guidelines.

Conclusions:

• Optimizing antibacterial therapy for ABS is crucial for clinical success and resistance prevention.
• Understanding guideline variations is important for clinicians.
• New agents like telithromycin offer potential advancements in ABS treatment.